Andarine
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.
Andarine is used for harder-looking recomposition, strength retention, and a drier cut.
The defining safety issue is vision: yellow tint or poor night adaptation should be treated as a stop signal, especially for users who drive, fly, shoot, or work in low light.
Andarine is used for harder-looking recomposition, strength retention, and a drier cut. It is less mass-forward than LGD-4033 and less shutdown-heavy than S-23, but it is still an androgenic SARM with real suppression and monitoring needs.
Yellow-tinted vision, night-vision difficulty, HPTA suppression, lipid/liver marker movement, acne or hair shedding in susceptible users, and female virilization risk.
A dry, cosmetic cutting SARM for users who accept the vision-side-effect tradeoff and want something milder than the most suppressive SARMs.
Users report visible hardening and modest strength retention more reliably than dramatic scale gain. The main reason people stop is not lack of effect; it is the vision side effect becoming annoying or unsafe.
Intro
Andarine, usually called S-4, is an early selective androgen receptor modulator developed in the same broad research era as other nonsteroidal SARMs.
In the self-experimenter world it occupies a specific lane: dry cutting, cosmetic hardness, and strength retention with a side-effect signature almost everyone knows about - yellow-tinted vision and poorer night vision. S-4 is not the gentle wellness version of an anabolic. It binds the androgen receptor, can suppress endogenous testosterone, can move lipids and liver enzymes, and is inappropriate for pregnancy or women trying to avoid virilization. Its advantage is that the community generally frames it as less brutally suppressive than S-23 or high-dose RAD-140, while still more visibly cosmetic than many mild recomp compounds. The evidence base is mixed. Formal SARM literature supports the mechanism and class risks; practical dosing and stop rules come from community protocols, logs, and corpus assertions. The article should therefore be read as a practical SARM briefing, not a clinician-approved protocol.
Observed Effects
Dry recomposition. Community use centers on a harder, leaner appearance, improved muscle definition, and strength retention during a calorie deficit.
Reports often describe Andarine as visually useful when the user is already fairly lean. Modest muscle support. S-4 is not usually chosen for maximal bulking. Users compare it more often with ostarine-style recomp or cutting stacks than with LGD-4033 mass cycles. Vision effects are dose-limiting. Yellow tint, light/dark adaptation problems, and reduced night visibility are the signature effect. The issue is usually described as reversible after stopping, but it can make driving at night or working in low light a hard stop. Suppression still matters. Andarine is commonly treated as less suppressive than S-23, but not non-suppressive. Libido, mood, testosterone, LH/FSH, and post-cycle recovery still need attention, especially at 50 mg/day-style community doses.
Field Reports
Reports usually describe a drier look, more visible definition, better workouts in a deficit, and moderate strength retention.
The positive logs are strongest when the user is already lean enough for cosmetic hardness to show. Negative reports center on yellow vision, night-vision difficulty, and annoyance with daily functioning. Some users tolerate the visual shift; others stop quickly because driving, screens, or low-light settings feel wrong. Suppression reports are less dramatic than S-23's reputation but still real. Users who treat S-4 as non-suppressive are the ones most likely to be surprised by low libido, flat mood, or post-cycle bloodwork.
Community Consensus
Andarine's reputation is unusually specific: people remember the vision side effect as much as the physique effect.
That makes community consensus cleaner than many SARMs. The advocate case is dry cutting, hardness, and a manageable intermediate risk profile. The skeptic case is that any compound that can make night driving feel sketchy is not worth a few weeks of cosmetic improvement. Older SARM community discussions treat S-4 as part of the classic trio with ostarine and LGD-4033, but newer users often skip it because ostarine feels simpler and RAD/LGD/S-23 feel stronger. S-4 survives because it has a distinct cosmetic lane. The most useful community rule is not a dose; it is a stop condition. Vision effects are not something to brag through. If the compound changes low-light function, the protocol has crossed from side-effect management into real-world safety friction.
Risks & Monitoring
The hallmark adverse effect is visual disturbance. Users report yellow-tinted vision, trouble adapting between bright and dark environments, and poorer night vision.
This is not a vague wellness complaint; it can change whether someone should drive at night. The practical stop rule is simple: if vision changes interfere with normal safety, discontinue rather than trying to push through. Endocrine suppression. S-4 can suppress the HPTA. Men may see lower testosterone, lower LH/FSH, libido changes, fatigue, and post-cycle sluggishness. The risk is usually framed as moderate compared with S-23, but dose and duration still matter. Lipids, liver, and cardiovascular markers. SARM safety literature and monitoring guides flag HDL reduction, LDL changes, liver enzyme elevations, and possible cardiovascular concern across the class. Andarine users should not skip CMP, fasting lipids, and blood pressure just because S-4 has an older mild reputation. Androgenic effects. Acne, oily skin, hair shedding in genetically susceptible users, irritability, and sleep changes can occur. Women carry the higher-consequence risk profile: menstrual disruption can be an early warning sign, and voice, clitoral, or hairline changes may not fully reverse.
For Women
Monitoring Panels
REQUIRED is a real safety gate. RECOMMENDED is the prudent default. OPTIONAL covers symptoms, risk factors, or tighter tracking.
Establishes the androgen baseline before an HPTA-suppressive SARM.
Shows whether gonadotropin signaling is already fragile before S-4 exposure.
Oral SARM use warrants liver and kidney baseline values.
HDL/LDL movement is a practical SARM risk marker and changes continuation decisions.
Provides a cardiovascular baseline before androgenic exposure.
Yellow tint, night-vision problems, or unsafe light/dark adaptation are dose-limiting stop signals.
Confirms endocrine recovery instead of guessing from libido or mood.
Confirms liver and lipid markers returned toward baseline after the cycle.
Avoid With
Do not combine Andarine with the following. Sorted highest-severity first.
Why:Andarine's signature visual disturbance can impair night visibility and light/dark adaptation.
What to do:This is a practical safety conflict, not just a comfort issue.
Why:Adds oral liver/lipid/cardio burden on top of S-4's SARM-class monitoring concerns.
What to do:Use a simpler protocol if markers are not being tracked.
Why:Androgen-receptor activity can disrupt cycles and cause virilizing effects.
What to do:Pick non-androgenic longevity or recovery compounds instead.
Why:Stacking SARMs compounds HPTA suppression and makes vision, mood, libido, and lipid issues harder to identify.
What to do:Avoid especially with S-23, RAD-140, LGD-4033, or YK-11 unless managing it as an advanced cycle.
Protocols By Goal
Cutting and hardening. Andarine fits best when the user wants a dry look, better definition, and strength retention during a deficit.
The protocol should be short, vision-aware, and paired with diet discipline rather than stacked into a chaotic SARM pile. Recomp. S-4 can make sense for users who want mild lean-mass support without the heavier suppression reputation of S-23. The tradeoff is that vision effects may interrupt the cycle before physique payoff peaks. Strength retention. Use as a support compound during a cut, not as a maximal strength agent. If the goal is aggressive strength gain, RAD-140, LGD-4033, testosterone, or traditional anabolic lanes are the more direct comparisons - with their own larger risks. Women. Do not use Andarine as a female longevity or wellness compound. It is androgenic; safer non-anabolic lanes should be chosen instead.
Dosing Details
No approved human performance dose exists. Community protocols commonly discuss 25-50 mg/day for 6-8 weeks, often split into two daily doses.
Some users start around 25 mg/day to assess vision effects before moving toward 50 mg/day. Conservative cut/recomp. 25 mg/day for 4-6 weeks. This is the most sensible learning range because the user can evaluate vision, libido, mood, and training response before committing to a longer cycle. Common community cycle. 50 mg/day for 6-8 weeks, usually split AM/PM. This is where vision complaints become more relevant and where post-cycle labs matter more. Stop rule. Do not normalize unsafe night vision. If yellow tint, low-light adaptation, or driving visibility becomes meaningful, stop or reduce exposure. Continuing because the physique effect is working is the classic Andarine mistake.
Stacks & Alternatives
Commonly discussed as a milder recomp/cutting stack, but stacking SARMs adds suppression and makes side effects harder to attribute.
Used by some cutting communities for endurance/fatigue support without adding direct androgen-receptor suppression; it has its own safety debate.
Advanced users may use a testosterone base when suppression is expected. That changes the plan into endocrine-managed anabolic territory.
Alternatives
Stack Cost
Andarine's stack tax is moderate: vision safety is the unique limiter, while SARM-class suppression, lipids, and liver monitoring still consume capacity.
The practical limiting side effect is visual disturbance: yellow tint, night-vision difficulty, and light/dark adaptation problems that can affect daily safety.
Andarine is less shutdown-heavy than S-23 but still suppresses endogenous androgen signaling enough to require baseline and post-cycle labs.
SARM-class safety literature and monitoring guides support CMP, fasting lipids, and blood-pressure checks.
Androgenic activity conflicts with pregnancy and female virilization avoidance; fertility goals raise caution for men as well.
- ·Do not use if night vision is safety-critical.
- ·Avoid stacking with stronger suppressive SARMs unless managing a full advanced cycle.
- ·Run baseline and post-cycle endocrine/lipid/liver labs.
- ·Vision stop rules
- ·Baseline and post-cycle labs
- ·Blood-pressure tracking
- ·Accurate oral dosing
- ·Cycle break/recovery planning
Ordinary misuse is usually less catastrophic than S-23, but vision effects, suppression, and lab movement make it more than beginner_ok.
- ·Night driving is unavoidable
- ·No post-cycle labs
- ·Female user avoiding virilization
- ·Poor lipids/liver enzymes
- ·Near-term fertility goals
Stopping usually resolves vision complaints, but endocrine recovery still needs confirmation.
- ·vision normalization period
- ·libido dip
- ·fatigue
- ·testosterone/LH/FSH recovery
- ·strength regression
Start conservatively, avoid night-driving exposure, and stop if function is impaired.
Use baseline/post labs and plan recovery support before starting.
Avoid routine female use and stop immediately if exposed.
The signature vision side effect can create real safety risk.
S-4 is androgenic and can disrupt cycles or virilize.
Even moderate SARM suppression can become a hard recovery problem on a fragile baseline.
SARM-class lipid/liver movement can worsen the existing marker problem.
Practical Setup
Forms. Andarine is commonly sold as oral liquid or capsules. Liquid products require accurate measuring; capsules depend on label accuracy and batch testing.
Cycle length. Most community cycles are 6-8 weeks. Shorter exposure is reasonable when testing vision response. Daily life fit. Users who drive at night, work in dark environments, shoot, fly, operate machinery, or rely on precise color/light perception should avoid S-4 or set a very low threshold for stopping. Budget. Labs, testing quality, and recovery support are part of the cost. The cheapest bottle is not the cheapest protocol if it produces marker movement or forces early discontinuation. Who should skip it. Beginners who have not run labs, women avoiding androgenic changes, users with poor lipids or liver enzymes, near-term fertility goals, and anyone unwilling to stop for visual disturbance.
Mechanism Deep Dive
Androgen receptor modulation. Andarine binds androgen receptors and aims to produce anabolic signaling in muscle and bone with less prostate/skin stimulation than traditional anabolic-androgenic steroids.
Selectivity is relative, not immunity from systemic androgen effects. Dry cosmetic signal. S-4 does not aromatize into estrogen, so users do not expect estrogenic water retention. The dry look comes from androgenic signaling plus the absence of added estrogen/water effects, not from fat loss magic. Vision side effect hypothesis. Andarine's distinctive yellow/night-vision effect is commonly attributed to interaction with retinal signaling or off-target visual-cycle effects. The exact consumer-use mechanism is not settled, but the practical phenotype is consistent enough to drive stop rules. Suppression and class risk. Like other SARMs, S-4 can reduce endogenous gonadotropin/testosterone signaling. SARM-class literature also supports monitoring for lipid, liver, and cardiovascular changes, especially with unapproved recreational products.
Evidence Index
Quantitative claims trace to these source studies. Population, dose, and study type matter — claims from HIV-lipodystrophy trials don't transfer cleanly to healthy adults; data from supraphysiologic doses doesn't apply at TRT.
Community protocols commonly discuss 25-50 mg/day for 6-8 weeks.
Self-experimenter protocol range, not approved clinical dosing.
Some users start around 25 mg/day to assess vision effects before moving toward 50 mg/day.
Vision tolerability, not efficacy, is the main escalation limiter.
Most community cycles are 6-8 weeks.
Cycle length reflects community practice and should be shortened if vision or labs deteriorate.
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.